Lu Ping, Ma Yifei, Wei Shaozhong, Liang Xinjun
Department of Medical Oncology, Hubei Cancer Hospital, The Seventh Clinical School Affiliated of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Gastrointestinal Oncology Surgery, Hubei Cancer Hospital, The Seventh Clinical School Affiliated With Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Med (Lausanne). 2021 Mar 1;8:621592. doi: 10.3389/fmed.2021.621592. eCollection 2021.
The serum albumin-to-globulin ratio (AGR) may be a useful prognostic factor for various cancers. This study aimed to evaluate the prognostic value of the AGR in patients with metastatic non-small-cell lung cancer (NSCLC). A retrospective study was conducted on patients with stage IV NSCLC diagnosed in Hubei Cancer Hospital from July 2012 to December 2013. The formula for calculating the AGR was serum albumin/total protein-serum albumin. The chi-square test or Fisher's exact test was used to analyze the classified variables. The Kaplan-Meier method was used to analyze the overall survival (OS) rate, which was plotted with the R language. The impact of the AGR on OS and progression-free survival (PFS) was analyzed by a multivariate Cox proportional hazard model. A total of 308 patients were included in the study population. The optimal cutoff values for the AGR in terms of OS and PFS were 1.12 and 1.09, respectively, as determined by X-Tile software. Kaplan-Meier curve analysis showed that the difference in survival rate between patients with different AGR levels was statistically significant ( = 0.04). The OS of patients with a high AGR (≥1.12) was longer than that of patients with a low AGR (<1.12). PFS in the high AGR group were better than those in the low AGR group (16.90 vs. 32.07months, = 0.008). The univariate and multivariate models proved that the AGR was an independent prognostic factor in metastatic NSCLC patients in terms of both OS ( = 0.009, hazard ratio [HR] = 0.55, 95% confidence interval [95% CI] = 0.35-0.86) and PFS ( = 0.004, HR = 0.55, 95% CI = 0.37-0.83). The AGR, which is measured in routine clinical practice, is an independent prognostic factor in terms of OS and PFS in metastatic NSCLC and can serve as a prognostic tool for metastatic NSCLC.
血清白蛋白与球蛋白比值(AGR)可能是多种癌症有用的预后因素。本研究旨在评估AGR在转移性非小细胞肺癌(NSCLC)患者中的预后价值。对2012年7月至2013年12月在湖北省肿瘤医院确诊的IV期NSCLC患者进行了一项回顾性研究。计算AGR的公式为血清白蛋白/(总蛋白 - 血清白蛋白)。采用卡方检验或Fisher精确检验分析分类变量。采用Kaplan-Meier法分析总生存率(OS),并用R语言绘制生存曲线。通过多变量Cox比例风险模型分析AGR对OS和无进展生存期(PFS)的影响。研究人群共纳入308例患者。经X-Tile软件确定,AGR在OS和PFS方面的最佳截断值分别为1.12和1.09。Kaplan-Meier曲线分析显示,不同AGR水平患者的生存率差异具有统计学意义(P = 0.04)。AGR高(≥1.12)的患者OS长于AGR低(<1.12)的患者。高AGR组的PFS优于低AGR组(16.90对32.07个月,P = 0.008)。单变量和多变量模型证明,AGR在OS(P = 0.009,风险比[HR]=0.55,95%置信区间[95%CI]=0.35 - 0.86)和PFS(P = 0.004,HR = 0.55,95%CI = 0.37 - 0.83)方面均为转移性NSCLC患者的独立预后因素。在常规临床实践中测量的AGR是转移性NSCLC患者OS和PFS的独立预后因素,可作为转移性NSCLC的预后工具。